iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IRadimed excels in Q4 2022, anticipates strong growth in 2023

IRadimed's Q4 2022 showcased exceptional performance with record revenues and strong earnings, setting the stage for continued growth.
While facing challenges such as margin pressures and tax expenses, the company's optimistic outlook for 2023 presents growth opportunities.
Strategic focus on revenue expansion, margin improvement, and cost management will be key to sustaining profitability and maximizing shareholder value.
Investors can look forward to potential earnings growth and market positioning strength in the upcoming year.

IRadimed reports record revenue and earnings growth, anticipates FDA clearance

IRadimed's Q1 2023 performance was strong, with record revenue and earnings growth. Despite supply chain challenges, the company is optimistic about FDA clearance for a new product and expects pricing trends to remain favorable.

iRadimed posts record revenue and earnings, raises guidance optimistically

iRadimed delivered exceptional financial performance in Q2 2023, achieving record revenue and substantial earnings growth, driven by strong sales across all product categories.
The company's operational efficiency, margin expansion, and strategic initiatives position it well for sustained growth and profitability in the future.
With raised guidance, innovative product developments, and expanding market presence, iRadimed is poised for continued success and value creation for shareholders.
Investors can be optimistic about iRadimed's performance, as the company demonstrates resilience, growth potential, and a solid foundation for future expansion.

iRadimed reports record Q3 earnings, raises 2023 guidance optimistically

iRadimed (IRMD) delivered exceptional Q3 '23 results, with record revenue, earnings growth, and strong product sales, positioning the company for continued success.
While facing challenges in meeting Q4 '23 targets and securing regulatory approvals, iRadimed's proactive strategies and market opportunities offer avenues for sustained growth.
With raised guidance for 2023 and promising product developments, iRadimed has the potential to capitalize on its strengths and navigate industry challenges effectively.
Investors and stakeholders can look to iRadimed's performance, product innovation, and regulatory progress as indicators of the company's resilience and growth prospects.

iRadimed (IRMD) reports record Q4 revenue, eyes international expansion

iRadimed's Q4 2023 performance marked by record revenue, strong device sales, and margin challenges. The company's focus on product growth and international expansion presents opportunities for future revenue and earnings growth.

iRadimed (IRMD) posts record revenue and earnings growth in Q1 2024

iRadimed (IRMD) delivered strong financial performance in Q1 2024, driven by record revenue, earnings growth, and robust demand for MR patient monitor products.
Despite challenges such as submission delays and significant investment in a new facility, the company remains focused on innovation and shareholder value.
With opportunities for market expansion, product clearance, and operational enhancements, iRadimed is poised for continued growth and competitive strength in the medical device industry.

iRadimed (IRMD) achieves record Q2 earnings, eyes FDA clearance

iRadimed's Q2 2024 performance reflects robust revenue growth, improved margins, and enhanced operational efficiency, positioning the company for continued success.
While facing challenges in international sales and operational delays, iRadimed's focus on cost management and product development presents opportunities for future growth.
Overall, iRadimed's financial outlook remains positive, with strong cash flow, new product developments, and strategic initiatives driving long-term value for investors.

iRadimed posts record Q3 earnings, eyes new product launches

iRadimed's Q3 2024 performance reflects strong revenue growth, operational efficiency, and effective cost management.
While facing challenges in product clearance and sales transition, the company is well-positioned to capitalize on growth opportunities.
Strategic focus on new product launches and international market expansion could drive future revenue and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable

WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune's 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024

IRADIMED CORPORATION. (NASDAQ:IRMD ) Q3 2024 Earnings Conference Call October 31, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Third Quarter of 2024 Financial Results Conference Call.

IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript

IRadimed (IRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.43 per share a year ago.

IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates

WINTER SPRINGS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and a non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st

WINTER SPRINGS, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference.

IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

WINTER SPRINGS, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that the Company will be participating in the Lake Street 8 th  Annual Best Ideas Growth "Big 8" Conference.

IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas Growth “Big 8” Investor Conference

IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2024 Results Conference Call August 1, 2024 12:00 PM ET Company Participants Roger Susi - President and Chief Executive Officer Matt Garner - Controller Conference Call Participants Frank Takkinen - Lake Street Capital Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Second Quarter of 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, August 1, 2024, and contains time-sensitive accurate information only today.

IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript

IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.36 per share a year ago.

IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates

WINTER SPRINGS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and six months ended June 30, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the same day beginning at 12:00 p.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st

WINTER SPRINGS, Fla., June 07, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD.

IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market

IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2024 Results Conference Call May 2, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Frank Takkinen - Lake Street Capital Operator Welcome to IRADIMED CORPORATION First Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode, and at the end of the call, we will conduct a question-and-answer session.

IRADIMED CORPORATION (IRMD) Q1 2024 Earnings Call Transcript

WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2nd

WINTER SPRINGS, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, the Company's President and Chief Executive Officer, will present at the 36th Annual Roth Conference in Laguna Niguel, CA.

IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference

IRadimed Corporation (IRMD) Q4 2023 Earnings Call Transcript

WINTER SPRINGS, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months and year ended December 31, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results

WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.

WINTER SPRINGS, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) --  IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (‘MRI”) compatible medical devices, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023. The fourth-quarter revenue totaled approximately $17.5 million, bringing revenue for 2023 to approximately $65.6 million, up 23% from the prior year.

IRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue

WINTER SPRINGS, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices, today announced that the Company will be participating in the upcoming 42nd Annual J.P.

IRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference

WINTER SPRINGS, Fla., Dec. 12, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company's outstanding common stock. The regular quarterly dividend is $0.15 per share. The special cash dividend and the quarterly dividend are payable on January 12, 2024, to shareholders of record at the close of business on December 22, 2023.

IRADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a Special Cash Dividend of $0.48 per share

Graham Corp

HCI Group

Limbach Holdings

Manitex

We have narrowed our search to five small-cap (market capital < $1 billion) stocks. These are: HCI, LMB, IRMD, GHM, MNTX.

5 Small Hidden Gems for the Rest of 2023

IRadimed Corporation (IRMD) Q3 2023 Earnings Call Transcript

News for iRadimed Stock (IRMD)